Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (177Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors,Cancer Biotherapy and Radiopharmaceuticals

当前位置： X-MOL 学术 › Cancer Biother. Radiopharm. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (177Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors
Cancer Biotherapy and Radiopharmaceuticals ( IF 2.4 ) Pub Date : 2022-02-08 , DOI: 10.1089/cbr.2021.0053
Swayamjeet Satapathy ₁ , Anish Bhattacharya ₁ , Ashwani Sood ₁ , Rakesh Kapoor ₂ , Rajesh Gupta ₃ , Apurva Sood ₁ , Prashant Sharma ₄ , Divya Khosla ₂ , Bhagwant Rai Mittal ₁

Affiliation

Background: Chronic inflammation has been linked to the development and prognosis of neuroendocrine tumors (NETs). The current study intended to evaluate the role of peripheral hematological inflammatory markers, viz. the platelet–lymphocyte ratio (PLR), neutrophil–lymphocyte ratio, and monocyte–lymphocyte ratio, as predictors of treatment outcomes in patients with advanced NETs after Lutetium-177(¹⁷⁷Lu)-DOTATATE therapy.

中文翻译：

血液学标志物作为晚期神经内分泌肿瘤患者使用镥 177 (177Lu)-DOTATATE 治疗结果的预测因子

背景：慢性炎症与神经内分泌肿瘤 (NET) 的发展和预后有关。目前的研究旨在评估外周血液炎症标志物的作用，即。^{血小板 - 淋巴细胞比率 (PLR)、中性粒细胞 - 淋巴细胞比率和单核细胞 - 淋巴细胞比率，作为 Lutetium-177( 177} Lu)-DOTATATE 治疗后晚期 NET 患者治疗结果的预测因子

更新日期：2022-02-09

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11